The driver landscape of sporadic chordoma
- PMID: 29026114
- PMCID: PMC5638846
- DOI: 10.1038/s41467-017-01026-0
The driver landscape of sporadic chordoma
Abstract
Chordoma is a malignant, often incurable bone tumour showing notochordal differentiation. Here, we defined the somatic driver landscape of 104 cases of sporadic chordoma. We reveal somatic duplications of the notochordal transcription factor brachyury (T) in up to 27% of cases. These variants recapitulate the rearrangement architecture of the pathogenic germline duplications of T that underlie familial chordoma. In addition, we find potentially clinically actionable PI3K signalling mutations in 16% of cases. Intriguingly, one of the most frequently altered genes, mutated exclusively by inactivating mutation, was LYST (10%), which may represent a novel cancer gene in chordoma.Chordoma is a rare often incurable malignant bone tumour. Here, the authors investigate driver mutations of sporadic chordoma in 104 cases, revealing duplications in notochordal transcription factor brachyury (T), PI3K signalling mutations, and mutations in LYST, a potential novel cancer gene in chordoma.
Conflict of interest statement
The authors declare no competing financial interests.
Figures


Similar articles
-
Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma.Hum Genet. 2014 Oct;133(10):1289-97. doi: 10.1007/s00439-014-1463-z. Epub 2014 Jul 4. Hum Genet. 2014. PMID: 24990759 Free PMC article.
-
T (brachyury) gene duplication confers major susceptibility to familial chordoma.Nat Genet. 2009 Nov;41(11):1176-8. doi: 10.1038/ng.454. Epub 2009 Oct 4. Nat Genet. 2009. PMID: 19801981 Free PMC article.
-
'The chicken or the egg?' dilemma strikes back for the controlling mechanism in chordoma(#).J Pathol. 2012 Nov;228(3):261-5. doi: 10.1002/path.4102. J Pathol. 2012. PMID: 22952146
-
Novel therapeutic targets in chordoma.Expert Opin Ther Targets. 2012 Nov;16(11):1139-43. doi: 10.1517/14728222.2012.714772. Epub 2012 Aug 4. Expert Opin Ther Targets. 2012. PMID: 22860993 Review.
-
Notochordal Tumors: An Update on Molecular Pathology with Therapeutic Implications.Surg Pathol Clin. 2017 Sep;10(3):637-656. doi: 10.1016/j.path.2017.04.008. Epub 2017 Jun 29. Surg Pathol Clin. 2017. PMID: 28797506 Review.
Cited by
-
The early evolutionary landscape of osteosarcoma provides clues for targeted treatment strategies.J Pathol. 2021 Aug;254(5):556-566. doi: 10.1002/path.5699. Epub 2021 May 25. J Pathol. 2021. PMID: 33963544 Free PMC article.
-
Aldehyde Dehydrogenase, a Therapeutic Target in Chordoma: Analysis in 3D Cellular Models.Cells. 2021 Feb 15;10(2):399. doi: 10.3390/cells10020399. Cells. 2021. PMID: 33672032 Free PMC article.
-
Role of immunotherapy in treatment refractory chordomas: review of current evidence.Front Surg. 2024 May 30;11:1375567. doi: 10.3389/fsurg.2024.1375567. eCollection 2024. Front Surg. 2024. PMID: 38881706 Free PMC article. Review.
-
The lysosomal trafficking regulator "LYST": an 80-year traffic jam.Front Immunol. 2024 May 7;15:1404846. doi: 10.3389/fimmu.2024.1404846. eCollection 2024. Front Immunol. 2024. PMID: 38774881 Free PMC article. Review.
-
Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?Biomedicines. 2021 Aug 19;9(8):1048. doi: 10.3390/biomedicines9081048. Biomedicines. 2021. PMID: 34440251 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous